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Serum amyloid A (SAA) is a precursor for the amyloid A in AA type of amyloidosis. Distribution of mast cells in tissues is similar to the
distribution of amyloid deposits in secondary AA-amyloidosis. Therefore, we studied whether mast cells could be involved in SAA metabolism.
Human mast cell line (HMC-1) cells were cultured with recombinant human apoSAA (rhSAA), and the production of tumour necrosis factor
(TNF)-α and interleukin (IL)-1β was determined by ELISA. RhSAA and human SAA (huSAA) were incubated with human chymase, tryptase or
with intact human mast cell (huMC) in cultures, and degradation of SAA was followed by gel electrophoresis, liquid chromatography and mass
spectrometry. SAA induced dose-dependent production of TNF-α and IL-1β in HMC-1 cells. Tryptase, chymase, and huMC granules degraded
efficiently the SAA protein. Degradation of SAA by tryptase, but not by chymase, released a highly amyloidogenic N-terminal fragment of SAA.
Finally, incubation of huMC with rhSAA alone resulted in degradation of SAA and formation of protofibrillar intermediates. These results suggest
a pathogenic role for mast cells in AA-amyloidosis.
© 2006 Elsevier B.V. All rights reserved.Keywords: Serum amyloid A; AA-amyloidosis; Amyloid fibril formation; HMC-1; Mast cell proteases1. Introduction
The main feature of amyloidosis is deposition of proteina-
ceous insoluble fibrils in tissues which results in organ damage.
In secondary amyloidosis or AA-amyloidosis, the fibrillar part
of amyloid deposits comprises of amyloid A (AA) which is
derived from the circulating precursor protein, serum amyloid A
(SAA) [1]. AA-amyloidosis occurs secondary to chronic
inflammatory diseases such as rheumatoid arthritis, Crohns
disease, the Familial Mediterranean Fever or as a result of
chronic infection [2].
Serum level of SAA, an acute-phase protein, may be
increased as much as 1000-fold during acute-phase response
to inflammation, infection or trauma [3]. SAA is mainly
produced in the liver but the expression of SAA mRNA and
SAA protein has been demonstrated also in various other cell
types [4], in the brain tissue of Alzheimer patients [5], and in the⁎ Corresponding author. Tel.: +358 9 19125203; fax: +358 9 19125206.
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doi:10.1016/j.bbadis.2006.01.001synovial tissue of joints [6]. SAA production is up-regulated by
proinflammatory mediators, notably the interleukins IL-1 and
IL-6 and the tumour necrosis factor TNF-α [7], and conversely,
SAA has been shown to induce the production of cytokines in
THP-1 monocytes and in neutrophils [8–10].
The mechanisms of amyloid formation in systemic AA-
amyloidosis are not fully understood but it is known that
continuously elevated SAA levels are critical in the pathogen-
esis of this disease [11]. It has been proposed that partially
degraded SAA fragments are more susceptible to fibril
formation. A critical role for macrophages in degradation of
SAA and in amyloid formation has been suggested [12].
Mast cells reside in connective tissue and in mucosal
membranes and are a part of the immune system. In addition to
histamine, mast cells produce proinflammatory mediators, such
as various cytokines [13]. Mast cells are also a rich source of
serine proteases, most notably chymase and tryptase [14]. A
pathogenic role for mast cells has been implicated in allergic
diseases and recently also in inflammatory diseases, the prime
example of which is rheumatoid arthritis [15]. Interestingly, the
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distribution of amyloid deposits [16]. For example, in renal AA-
or immunoglobulin light chain (AL) amyloidosis increased
density of interstitial mast cells has been found in the affected
kidney [17,18]. This clustering may be due to the fact that SAA
can act as a mast cell chemoattractant [19,20].
The aim of the present study was to investigate for any
interaction between mast cells and SAA, and to elucidate
whether such interaction could be involved in amyloidogenesis.
We found that SAA activates HMC-1 and huMC cells which, in
turn, results in the degradation of SAA into an amyloidogenic
fragment and the formation of protofibrillar intermediates.
2. Materials and methods
2.1. Materials
Recombinant human SAA (rhSAA) was purchased from Peprotech EC Ltd.
(London, UK). The amino acid sequence of rhSAA corresponds to the sequence
of SAA 1α isotype except for addition of Met at the N-terminus, substitution of
Asp for Asn at position 60 and substitution of His to Arg at position 71. These
positions are not in the region reported to be critical for the fibrillogenesis [21].
Human Serum Amyloid A (huSAA) was purchased from The Binding Site (San
Diego, CA, USA). Chymase purified from the human skin mast cells and
tryptase purified from the human lung mast cells were from Calbiochem (La
Jolla, CA, USA). Human albumin, Ca2+ ionophore A23187 and monothiogly-
serol were from Sigma (St. Louis, MO, USA). Iscove's modified Dulbecco's
medium and non-essential amino acids were from GIBCO Invitrogen
Corporation (Paisley, UK). Semi-purified human myeloma IgE and goat anti-
human IgE polyclonal antibody were purchased from Chemicon (Temecula, CA,
USA). Human recombinant stem cell factor (SCF) and interleukins IL-4, IL-6
and IL-10 were from R&D Systems (Minneapolis, MN, USA).
2.2. Culture and stimulation of HMC-1 cells and of human mast cells
Human mast cell line (HMC-1) [22] cells were maintained in Iscove's
modified Dulbecco's medium supplemented with 10% heat-inactivated fetal calf
serum (FCS), 0.1 μM non-essential amino acids, 1.2 mM monothioglycerol and
100 U/ml penicillin–100 μg/ml streptomycin at 37 °C in 5% CO2. For cytokine
assays, cells (1×106 cells/ml) were incubated for 24 h in the culture medium
containing intact rhSAA at concentration of 3–120 μg/ml or denaturated rhSAA
at 60 μg/ml or human albumin at 120 μg/ml. PMA (50 ng/ml) and Ca2+
ionophore A23187 (0.5 μM) were used to chemically activate HMC-1 cells [23].
After stimulation, the culture medium was collected by centrifugation and
cytokine concentrations were determined from the supernatants by a commercial
TNF-α or IL-1β ELISA kit (R&D Systems, Minneapolis, MN, USA or
BioSource Europe S.A., Nivelles, Belgium).
Human mast cells (huMCs) were cultured from cord blood or peripheral
blood CD34+ progenitor cells as described [24], with modifications. Shortly, the
cord blood stem cells were cultured in Dulbecco's modified medium containing
10% heat-inactivated FCS. In addition, it was supplemented with 80 ng/ml SCF,
50 ng/ml IL-6 and 10 ng/ml IL-10 for the first 1–3 weeks, with 80 ng/ml SCF for
the following 4–8 weeks, and with 80 ng/ml SCF and 10 ng/ml IL-4 after
8 weeks. The cells of peripheral blood were cultured in serum-free conditions in
Dulbecco's modified medium containing 100 U/ml penicillin and 100 μg/ml
streptomycin, and 100 ng/ml of SCF. After 4 weeks, 50 ng/ml of IL-6 was added
to the medium, and after 8 weeks, 10 ng/ml of IL-4 was added.
For histamine release assay, the huMCs (1.7×105 cells/ml) were first coated
with 6 μg/ml human myeloma IgE for 2 h in +37 °C, after which they were
washed and then incubated either with 0–120 μg/ml rhSAA for 1 h followed by
incubation with 10 μg/ml goat anti-IgE for 1 h or only with 0–120 μg/ml
rhSAA. After stimulation, the granule-containing cell culture medium was
collected after sedimentation of the cells by gentle spinning (5 min, RT, 200×g).
The histamine concentrations in the supernatants were determined by a
commercial histamine ELISA kit (IBL, Hamburg, Germany).2.3. Degradation of SAA
For enzyme digestion experiments, 6 μg of rhSAA or huSAA were
incubated at +37 °C with 0.01 BTEE units of human chymase and/or 3.2 mU of
human tryptase in PBS pH 7.4. Samples taken after 0 and 2 h of incubation were
analyzed using Tricine–SDS-PAGE [25] with 18%, 10% and 4% separating,
spacing and stacking layers, respectively. The gels were prefixed with 0.2%
glutaraldehyde and 30% ethanol in 0.2 M sodium acetate for 1h and then stained
by Coomassie blue (BioRad, Hercules, CA, USA). In addition to gel
electrophoresis, the rhSAA digests were analyzed by high performance liquid
chromatography connected to a mass spectometer (HPLC-MS/MS) using a
linear acetonitrile gradient (9–73% in 135 min) with PepMap C18 micro column
(FUS-15-03-C18-PM, 3 μm, 100 Å) on Famos/Switchos/Ultimate HPLC
system (LC-Packings, Amsterdam, Netherlands) that was connected on-line to
Esquire 3000 Plus Ion-Trap-MS (Bruker Daltonics, Bremen, Germany). The
enzyme activity was optimized to result in a slower degradation of rhSAA.
To study the degradation of SAA in huMC-conditioned medium, huSAA
(160 μg/ml) or rhSAA (120 μg/ml) were added to the cell culture medium
collected from IgE-activated huMC cultures and the mixture was incubated for
0–24 h at +37 °C. Samples were collected at different time points during
incubation and analyzed with 18–10–4% Tricine–SDS-PAGE or HPLC
(conditions as above).
In the degradation studies with huMC cultures, the experimental conditions
were similar to those in the histamine release assay, except that rhSAAwas used
at 100–300 μg/ml. The cell cultures were cultured in the presence of rhSAA for
4 days at +37 °C, after which the culture media were collected after
sedimentation of the cells by gentle spinning. Medium samples were analyzed
using 16.5–10–4% Tricine–SDS-PAGE and HPLC-MS (conditions as above).
A longer huMC experiment was also performed. HuMCs were cultured in the
presence of rhSAA for 7 days, with additions of rhSAA on days 2, 4 and 6. The
starting concentration of rhSAAwas 500 μg/ml and each addition corresponded
to a total concentration of 100 μg/ml. After 7 days, the cell culture medium was
collected and centrifuged at 200×g to remove the cells and then at 7000×g (RT,
15 min). The supernatants were analyzed by electron microscopy. Samples were
applied on Formvar- or Bioloform-coated grids (200 mesh), negatively stained
with 1% uranyl acetate, air-dried and examined with Jeol 1200-EX II
transmission electron microscope. The acceleration voltage of 60 kV was used.
2.4. Statistical analysis
The overall significance of differences between experimental groups was
analyzed with Friedman's Nonparametric Repeated Measurements ANOVA
(InStat 3 for Macintosh, Graph Pad Software, Inc.). The differences were
considered to be statistically significant when Pb0.05, in which case the
differences between individual experiment groups were further tested with
Dunn's multiple comparisons test. The data are shown as means±S.E.M.
3. Results
3.1. SAA induces cytokine production in human mast cells
First we studied the effect of SAA on cytokine production
by HMC-1 cells. As demonstrated in Fig. 1, a significant
and dose-dependent increase in TNF-α and IL-1β production
was observed in the presence of rhSAA. Compared to
nonactivated control the highest rhSAA concentration used
(120 μg/ml) increased the TNF-α production by 25-fold and
IL-1β production by 38-fold, the average concentrations
being 543±87 and 61±27 pg/ml/1×106 cells, respectively.
The induction of TNF-α production by SAA was comparable
to that observed with the combination of PMA and Ca2+
ionophore which is a very powerful stimulus of TNF-α
production in HMC-1 cells. The induction of IL-1β
production by SAA was even more pronounced than
Fig. 2. SAA induces histamine release from mature human mast cells (huMC).
The cells were coated with human myeloma IgE and then incubated with 0–120
μg/ml rhSAA. Histamine concentrations in the cell culture media were
determined with ELISA. Histamine concentrations of merely IgE-coated cells
are set to 1, concentrations depicted in the figure are expressed as x-fold. Values
are given as mean±S.E.M. from three individual experiments. *Pb0.05.
Fig. 1. RhSAA induces cytokine production in HMC-1 cells. The cells were incubated in the presence of rhSAA for 24 h after which the cytokine concentrations in the
cell culture media were determined with ELISA. Control cells (activated control) were activated with the combination of PMA and Ca2+ ionophore. Cytokine
concentrations of untreated cells are set to 1, concentrations depicted in the figure are expressed as x-fold. Values are given as mean±S.E.M.Means are calculated from
the values of 3 or 4 individual experiments. *Pb0.05.
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Interestingly the incubation of rhSAA (60 μg/ml) together
with PMA and Ca2+ ionophore resulted in further stimulation
of TNF-α production to more than 100-fold compared to
control, on average 2400 pg/ml/1×106 cells (data not
shown). This suggests that the effect of SAA is mediated
via a signal-transduction pathway other than calcium
signalling or protein kinase C. Human albumin and heat-
denatured rhSAA had no significant effect on cytokine
production implicating that the effect of SAA is specific and
that the native form of SAA is required for the effect.
3.2. SAA induces histamine release from human mast cells
HMC-1 cells do not possess intact IgE-receptors and
therefore the effect of SAA on IgE-induced histamine release
was studied in CD34+ stem cell derived human mast cells. Fig.
2 demonstrates a low but dose-dependent histamine release in
the presence of increasing concentrations of rhSAA (30–120
μg/ml). Compared to SAA-induced histamine release, the
histamine release observed with immunological activation was
clearly more pronounced, i.e., 25-fold higher than what was
released by SAA. SAA had no clear effect on the histamine
release if the mast cells had been immunologically activated
before the addition of the SAA (data not shown).
3.3. Degradation of SAA by mast cell derived proteases
As SAAwas found to be a strong activator of mast cells we
next elucidated whether mast cells could be involved in
catabolism of SAA and could thus possibly contribute to
generation of amyloid deposits. First, we studied the ability of
purified human mast cell proteases, tryptase and chymase,
which are the two major proteases of mast cells [26], to degrade
SAA. Both rhSAA and huSAAwere effectively degraded when
incubated with chymase or tryptase or with a combination of
both (Fig. 3A). This degradation was also followed by HPLC-
MS/MS. For these experiments the enzyme activity of tryptasewas lowered in order to be able to detect the very first
degradation products. The MS/MS analysis of the tryptase
digestion identified a peak (indicated by an asterisk; Fig. 3B) as
a compound corresponding to the mass of an N-terminal
fragment (residues 3–16; SFFSFLGEAFDGAR) of rhSAA,
which contains the major determinant in the amyloid formation
[21]. This fragment was not detectable in the chymase digest or
when both tryptase and chymase were used together.
3.4. Degradation of SAA by degranulating mast cells
Next, we studied the ability of cell culture supernatants
of IgE-activated human mast cells to degrade SAA. Mast
Fig. 3. (A) SDS-PAGE analysis of SAA degradation by purified mast cell proteases. 6 μg of rhSAA or huSAAwere incubated with human chymase (0.01 BTEE units)
and/or human tryptase (3.2 mU) in 20 μl of PBS at +37 °C. 10 μl samples were collected and run on a 18–10–4% Tricine–SDS-PAGE. Protein bands were visualized
by Coomassie blue. (C) Analysis of rhSAA degradation by micro-scale liquid chromatography. The two top graphs represent the digestion of rhSAA (3 μg) with a
mixture of human chymase (0.01 BTEE units) and human tryptase (3.2 mU) at two different time points. The two bottom graphs represent a similar digestion with
human tryptase alone. Both digestions were performed in PBS at +37 °C. 5 μl samples were injected into LC system. The amyloidogenic N-terminal fragment of
rhSAA is indicated by an asterisk.
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as described above and supernatants were incubated with
rhSAA or huSAA. The degradation of rhSAA and huSAA
was followed by Tricine–SDS-PAGE. As shown in Fig. 4A,
already after 2 h of incubation no intact huSAA was left and
the amount of intact rhSAA diminished as a function of
time. HPLC analysis of rhSAA 2 h samples revealed the
presence of the same amyloidogenic N-terminal SAA
fragment that was also seen when rhSAA was digested
with purified tryptase.The experiments above demonstrate that both purified mast
cell granule derived enzymes and huMC-conditioned media
can degrade SAA. Therefore, to demonstrate that SAA alone
can induce activation of MC resulting in degradation of SAA,
huMCs were cultured for 4 days in the presence of rhSAA.
The collected cell culture medium was analyzed using Tricine–
SDS-PAGE and HPLC-MS. Fig. 4B illustrates the degradation
of SAA protein during the incubation which is indicated by the
partial disappearance of intact SAA and appearance of smaller
molecular weight bands. This is further demonstrated in Fig.
Fig. 4. (A) SDS-PAGE analysis of SAA degradation by human mast cell
granules. RhSAA (120 μg/ml) and huSAA (160 μg/ml) were incubated in cell
culture medium, containing granules, collected from immunologically activated
human mast cells. 10 μl samples were collected and run on a 18–10–4%
Tricine–SDS-PAGE. Proteins were visualised by Coomassie blue. The protein
band of higher molecular weight seen in all lanes is a component of the cell
culture medium. (B) SDS-PAGE analysis of SAA degradation in human mast
cell culture. The cells were cultured in the presence of rhSAA (500 μg/ml) for 4
days. The cell culture medium was collected and 12 μl samples were run on a
16.5–10–4% Tricine–SDS-PAGE. Proteins were visualised by Coomassie blue.
(C) Analysis of rhSAA degradation in human mast cell culture by micro-scale
liquid chromatography. Human mast cells were cultured in the presence of
rhSAA (500 μg/ml) for 4 days without immunological activation. The cell
culture medium was collected and 5 μl samples were injected into LC system.
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Together, these data suggest that addition of SAA alone to
mast cell cultures is sufficient to induce degradation of the
SAA protein.Finally, we studied whether incubation of SAAwith cultured
mast cells can lead to amyloid formation. For this we set up an
experiment where human mast cells were cultured in the
continuous presence of rhSAA for 7 days. The amount of intact
rhSAA in the culture during the incubation was verified by
Tricine–SDS-PAGE. After 7 days cell culture media were
collected and then negatively stained with uranyl acetate and
examined with transmission electron microscope. As shown in
Fig. 5, fibril-like structures were found in the culture medium
collected from rhSAA-stimulated huMCs (images A and B) but
not in the medium that was collected from untreated cells
(image C). These structures do not resemble mature amyloid
fibrils as seen formed by synthetic peptides but they do possess
a typical appearance of protofibrils. This finding was further
supported by the fact that the N-terminal fragment of SAA
could not be detected by MS analysis on the cell culture samples
incubated for 4 days with SAA, suggesting that the fragment
was no longer in a soluble form.
4. Discussion
The results of the present study show that SAA can activate
human mast cells as indicated by the significant induction of
TNF-α and IL-1β production. The normal SAA levels in serum
vary between 1 and 5 μg/ml, but during inflammatory reaction
they can be increased up to 1000-fold higher values, reaching
levels of 500–1000 μg/ml. According to the present results,
such levels are sufficiently high to induce cytokine production
in mast cells. The mast cell-derived cytokines, again, can initiate
a local inflammatory reaction, ultimately resulting in tissue and
organ damage. In addition, mast cell derived cytokines can
contribute to further increase in SAA levels in serum by
stimulating the hepatic production.
The SAA fragments most commonly found in AA-fibrils are
68–76 amino acids in length [27]. However, the fibrils seem to
be heterogeneous containing a mixture of polypeptides of
different lengths [28,29]. In particular, the N-terminal region of
SAA has been shown to be a major determinant for amyloid
formation [21]. In addition, other proteins, and also heparin
which is a major constituent of mast cell granules, can promote
amyloidogenesis [30–32]. In this study, we demonstrated that
incubation of rhSAA with purified human mast cell tryptase
generated a highly amyloidogenic 14-aa N-terminal fragment of
SAA. Interestingly, an isolated chymotrypsin-like mast cell
protease has been shown to generate the N-terminus of the
Alzheimer amyloid-β protein [33], indicating that this type of
enzymes might also be involved in other type of amyloid
formation. Furthermore, activation of mast cells by SAA
resulted in degranulation of mast cells and thus in the release
of heparin into extracellular space. In other words, the
interaction of SAA with mast cells results in the production of
an amyloidogenic N-terminal fragment of SAA, and in the
release of heparin which might further enhance amyloid
formation.
Incubation of SAA with purified human chymase or with
both tryptase and chymase together resulted in the degradation
of the N-terminal amyloidogenic fragment of SAA. However,
Fig. 5. Electron microscopic analysis of fibril formation in human mast cell culture. The cells were cultured for 7 days in the presence of rhSAA with a starting
concentration of 500 μg/ml and additions corresponding to 100 μg/ml on days 2, 4 and 6. Cell culture media were collected, negatively stained with 1% uranyl acetate
and examined with transmission electron microscope. Images A and B represent media from cell cultures with rhSAA and C from untreated cells (negative control).
Magnifications 30,000× (B and C) or 25,000× (A). The bar shown in all images equals to 200 nm.
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cells containing the mast cell derived granules, left the
amyloidogenic fragment intact. This is somewhat surprising
as mast cell granules contain both tryptase and chymase. After
the release of granules into the extracellular medium, tryptase is
released from the exocytosed granules whereas chymase is
bound to the granule matrix. Therefore, it is possible that in the
presence of mast cell granules SAA is degraded mainly by
tryptase, as the degradation by chymase is prevented when the
carboxyterminal portion of SAA is tightly bound to the heparin
proteoglycan matrix [34]. It is also noteworthy that chymase,
unlike tryptase, is inactivated in vivo by several natural
inhibitors [35] present in the serum. Indeed, our in vitro
conditions may reflect the actual conditions in vivo, in which
the natural inhibitors of chymase, present in the extracellular
fluids, effectively inhibit the chymase released from activated
mast cells.
During prolonged inflammation in vivo, the levels of SAA in
serum are persistently high due to the hepatic production of
SAA induced by proinflammatory cytokines. According to our
hypothesis, SAA is degraded by mast cell-derived tryptase but
at the same time new intact SAA is delivered to the site. To
investigate the formation of amyloid in human mast cell
cultures, we set up an experiment where SAA was added into
the culture medium not only in the beginning of the incubation
but also during it, with two-day intervals. This was done to
ensure an excess of SAA throughout the experiment and a
parallel between our experimental conditions and the conditions
in vivo. EM analysis on the cell culture media revealed an
extensive formation of fibril-like structures and aggregates.
Interestingly, several recent papers suggest that protofibrils or
small oligomers are critical for the toxic effects of amyloid [36–
38]. Based on these findings, we would like to suggest that
human mast cells are capable of turning SAA protein into
amyloid.
Many of the tissues that are prone to develop amyloid
deposits contain also abundant number of mast cells. Therefore
it is reasonable to assume that there is a functional relationship
between SAA and mast cells during amyloidogenesis in the
affected tissues. We would like to propose that such interaction
between SAA and mast cells involves the following hypothet-
ical sequence of events. High levels of SAA activate mast cellsto degranulate and to release their stores of cytoplasmic neutral
proteases, notably tryptase. The tryptase-generated amyloido-
genic SAA fragment can activate amyloid formation, which is
further enhanced by the mast cell-derived heparin conceivably
serving as an additional amyloid-enhancing factor. The SAA-
induced secretion of cytokines by mast cells may contribute to
the hepatic production of SAA, creating a positive-feedback
loop to exist. The above outlined mast cell-dependent
processing of SAA could represent an additional pathway for
generation of amyloid.
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